CME

Host: Anita L. Nelson, MD Guest: Barbara Dehn, Np, FAANP, NCMP Understanding the physiologic basis for the vasomotor symptoms of perimenopause/menopause has led to an improved ability to match a therapeutic approach to each individual patient. New and improved agents are helping to facilitate this dynamic. Join Anita Nelson, MD, and Barbara Dehn, NP, as they provide insights into making the right treatment decision for each patient—one that includes ensuring patient preferences are considered.

Host: Raymond Townsend, MD Despite many available drug therapies, patients with hypertension continue to experience elevated blood pressures, putting them at risk for cardiovascular-related morbidities and mortality. However, renal denervation, a minimally invasive procedure, has been shown to result in sustained and durable reductions in blood pressure. Find out what this approach could mean for your patients.

Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C Guest: Frank dela Rama, RN, MS, AOCNS, AGN-BC Learn about the APP’s evolving role in caring for patients receiving PARP inhibitors for prostate cancer in this on-demand webcast capturing a live presentation by Clinical Nurse Specialist Frank dela Rama, RN, MS, AOCNS, AGN-BC.

Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C Guest: Rasheda Persinger MSN, AGNP-C, AOCNP Learn from a leading expert in the field about the most recent recommendations for biomarker/molecular testing and personalized treatment plans for patients with non-small-cell lung cancer (NSCLC) based on testing results.

Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C Guest: Mary Weinstein Dunn Learn about evolving standards in the care of patients with advanced renal cell carcinoma in this on-demand webcast capturing a live presentation by Mary Weinstein Dunn, MSN, NP-C, OCN, RN.

Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C Guest: Jeremy Force Get up to date on how APPs can optimize care for patients with HER2-positive breast cancer in this on-demand webcast capturing a live presentation by Dr Jeremy Force.

Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C Guest: Robert Lentz, MD Get up to date with this on-demand webcast from a live symposium focused on the latest approaches to treating patients with metastatic colorectal cancer, including immunotherapy and targeted therapy strategies.

Guest: Donna Ryan, MD Guest: Daniel Zalinov, PA-C Guest: Megan Adelman, PharmD, BCPS, BCGP, CDCES Experts review best practices for the incorporation of motivational interviewing and shared decision-making strategies to improve the treatment of obesity. Tune in with Dr. Megan Adelman, Clinical Pharmacist of Family Medicine at Cleveland Clinic Akron General in Ohio, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Daniel Zalinov, Physician Assistant who specializes in Internal Medicine at Atrium Health in Charlotte, North Carolina.

Guest: Joyce O'Shaughnessy, MD By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 50 years of age and 75% of cases among women over 50 years of age are classified as HR+/HER2-. Although endocrine therapy is employed as standard-of-care treatment for many patients with HR+/HER2- breast cancer, not all such patients respond to endocrine therapy, and many who do initially respond will relapse. CDK 4/6 inhibitors can help overcome mechanisms of endocrine resistance, decrease tumor cell growth, and act synergistically with anti-estrogens. Clinicians are faced with constant change in the breast cancer treatment landscape. Disease heterogeneity, drug resistance, and incorporation of genetic testing into the treatment formula for HR+/HER2- breast cancer patients are all things they must contend with. Understanding practice guideline recommendations and the evidence behind them will allow clinicians to better integrate CDK 4/6 inhibitors into their clinical practice. This Chairman’s Perspective activity features a highlight summary from a nationally recognized expert with relevant and timely information on HR+/HER2- BC, including the latest trial results and accumulating real-world evidence that demonstrates the efficacy and overall safety …

Guest: Donna Ryan, MD Guest: Caroline M. Apovian, MD, FTOS Guest: Susan M. Tiso, DNP, APRN, FNP-BC, FAANP Experts review guideline-recommended criteria for diagnosis and treatment of obesity and describe best practices for prioritization of obesity management. Tune in to learn more with Dr. Caroline Apovian, Co-Director at Center for Weight Management and Wellness at Brigham and Women’s Hospital in Boston, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Dr. Susan M. Tiso, Retired Family Nurse Practitioner from Family Medicine at the University of California, Irvine.

Guest: Caroline M. Apovian, MD, FTOS Guest: Daniel Zalinov, PA-C Guest: W. Scott Butsch, MD, MSc Experts provide practical suggestions for incorporating obesity management into clinical practice and designing a comprehensive obesity care clinic. Dive in for more with Dr. Caroline Apovian, Co-Director of Center for Weight Management and Wellness at Brigham and Women’s Hospital in Boston, Dr. Scott Butsch, Director of Obesity Medicine at Bariatric and Metabolic Institute in Cleveland, Ohio, and Daniel Zalinov, Physician Assistant of Internal Medicine at Atrium Health in Charlotte, North Carolina.

Host: Jonathan D. Schoenfeld, MD, MPhil, MPH Guest: Robert L. Ferris, MD, PhD The treatment of LA SCCHN has remained largely unchanged for >2 decades and the standard of care, concurrent chemoradiotherapy (CRT) with high-dose cisplatin, is associated with substantial toxicity and limited efficacy. Inhibitors of apoptosis proteins (IAPs) may well change that dynamic. Join Drs. Jonathan Schoenfeld and Robert Ferris as they focus attention on this unmet need and critically evaluate how therapeutic modulation of the apoptotic pathway may improve patient outcomes.

Host: Ezra Cohen, MD, FRCPSC, FASCO Guest: Sue S. Yom, MD, PhD The emergence of early clinical endpoints compared to the current gold standard of overall survival may change the landscape of how clinical trials are designed as well as how patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are managed. At the forefront of this change are unique small molecule agents that help to overcome the inhibitory influence of tumors on the apoptotic pathway. Join Drs. Ezra Cohen and Susan Yom as they focus on why utilizing early endpoints in clinical trials, and eventually the clinic, may provide therapeutic advantages compared to our current gold standard of overall survival.

Guest: Neeraj Agarwal, MD, FASCO Guest: Elena Castro, MD, PhD Guest: Neal Shore, MD, FACS Guest: Axel S. Merseburger, MD While the development of advanced prostate cancers is largely influenced by androgen receptor (AR) signaling, DNA-damage response (DDR) pathways also contribute to disease progression. AR axis-targeted therapies (ARATs) have been the standard of care for first-line mCRPC. Inhibiting PARP activity is an effective strategy for targeting malignant cells with limited DNA repair capacity due to DDR gene mutations, leading to synthetic lethality. There may be a synergy between ARATs and PARP inhibitors (PARPi), as ARATs can induce HRR deficiencies and PARP inhibitors can increase the activity of ARATs through AR-dependent transcription. Recent clinical trial results have demonstrated that the combination of PARPi with ARATs is safe and effective for the first-line treatment of patients with mCRPC, with 3 combinations now FDA-approved: olaparib + abiraterone, talazoparib + enzalutamide, and niraparib + abiraterone. This activity will provide expert contextualization of evidence from first-line mCRPC clinical trials exploring these combinations, including insights about the differentiation of both treatment and patient selection, as well as management of treatment-related toxicities. Given the differences in approvals and guidelines between the US and European context, this Ryder Cup themed Expert Panel Discussion will compare and contrast the approach in both regions, giving participants comprehensive education on …

Host: Bianca Weinstock-Guttman, MD This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.